Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria

Graphical abstract Highlights ► We developed a transcutaneous vaccine formulation using a hydrogel patch. ► We performed clinical trial for vaccination against tetanus and diphtheria in human. ► The vaccine formulation did not induce local or systemic severe adverse events. ► Toxoid-specific serum a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2012-02, Vol.30 (10), p.1847-1854
Hauptverfasser:	Hirobe, Sachiko, Matsuo, Kazuhiko, Quan, Ying-Shu, Kamiyama, Fumio, Morito, Hironori, Asada, Hideo, Takaya, Yusuke, Mukai, Yohei, Okada, Naoki, Nakagawa, Shinsaku
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult adverse effects Aged Allergy and Immunology animal experimentation Animals antibodies Antibodies, Bacterial - blood Antigens blood serum Clinical study death developing countries Diphtheria Diphtheria - prevention & control Diphtheria Toxoid - administration & dosage enzyme-linked immunosorbent assay Female Humans hydrocolloids Hydrogel patch Hydrogels Hydrogels - administration & dosage Hydrogels - pharmacology immune response immunoglobulin G Immunoglobulin G - blood Infectious diseases Influenza Male Medical research Methods Mice Middle Aged Pandemics Proteins Raman spectroscopy safety assessment Severe acute respiratory syndrome Skin - immunology t-test Tetanus Tetanus - prevention & control Tetanus Toxoid - administration & dosage toxicity Transcutaneous immunization Transdermal Patch - adverse effects vaccination Vaccination - methods Vaccines volunteers Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Graphical abstract Highlights ► We developed a transcutaneous vaccine formulation using a hydrogel patch. ► We performed clinical trial for vaccination against tetanus and diphtheria in human. ► The vaccine formulation did not induce local or systemic severe adverse events. ► Toxoid-specific serum antibody titers increased by application of the formulation. ► This formulation will enable mass treatment and increase of vaccination rates.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2011.12.130